



Bioactive Natural Products for Treatment of Human Disease

Guest Editor:

Dr. Hyun-jung Park

Department of Food Science and
Biotechnology, Kyonggi
University, Gyeonggi, Republic of
Korea

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editor

Dear Colleagues,

Natural products have a history of being used as traditional medicines in many countries for treating disease and maintaining health. Bioactive natural products are now regarded as an important repository for the development of potential novel drugs. Extensive research on the preventative and therapeutic effects of bioactive natural products necessitates regular reporting of the literature as to the updating potential roles of these compounds in different human diseases, such as cardiovascular disease, aging, obesity, and neurodegeneration.

With this Special Issue, we aim to provide the current findings on the pharmacological and clinical features of natural products with defined molecular compounds, the pharmacology of naturally occurring compounds, and the role of bioactive natural products in human health and disease.

Dr. Hyun-jung Park

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)